Login to Your Account



Alexion Tackles Rare Disease Affecting Infants

By Catherine Shaffer


Friday, February 11, 2011
Alexion Pharmaceuticals Inc. will tackle a new category of disease following its acquisition of key technology assets from Germany-based Orphatec Pharmaceuticals GmbH. Alexion will take over development of an investigational therapy for molybdenum cofactor deficiency (MoCD) Type A, a rare disease that causes brain damage and death in infants. The move follows a solid earnings report, featuring Soliris sales of $156 million for the fourth quarter.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription